Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy.

This study determined the residual concentration of terbinafine in cat hair after 14 days of oral treatment. Ten clinically normal cats were administered terbinafine orally at a daily dose of 34-45.7 mg kg(-1) for a total of 14 days. Areas of 15 cm(2) were shaved on the lateral thorax at day 0 and weekly for 8 weeks after the last dose of terbinafine. The hair samples were analysed by high-pressure liquid chromatography to determine the persistence of terbinafine over time. The mean terbinafine concentration in hair was 2.30 ng mg(-1) after 14 days of therapy. The half life was 1.84 weeks after the last dose of terbinafine. With a 99% confidence interval, the concentration of terbinafine remained in the cat hair at or above 0.03 ng mg(-1) (minimal inhibitory concentration (MIC)(90) = 0.03 microg mL(-1)) for 5.3 weeks. Slight deviations in the complete blood cell count and serum chemistry values were not attributed to terbinafine. Four cats experienced vomiting during the terbinafine treatment; two of these cats also experienced intense facial pruritus followed by a macular to papular skin reaction 7-14 days after the discontinuation of terbinafine. In summary, terbinafine persists in hair at concentrations above the MIC for several weeks after stopping medication, even after short-term therapy (14 days). These results suggest that pulse therapy of terbinafine should be further researched and potentially considered as a treatment modality for feline dermatophytosis, an approach that would decrease treatment duration while maintaining effectiveness.

[1]  P. Knoke Poster Abstracts , 2012, International Journal of Obesity.

[2]  K. Moriello,et al.  Recommendations for the management and treatment of dermatophytosis in animal shelters. , 2006, The Veterinary clinics of North America. Small animal practice.

[3]  J. Roujeau,et al.  Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus , 2005, Dermatology.

[4]  K. Moriello Treatment of dermatophytosis in dogs and cats: review of published studies. , 2004, Veterinary dermatology.

[5]  N. Ryder,et al.  In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. , 2002, Medical mycology.

[6]  T. Kotnik Drug efficacy of terbinafine hydrochloride (Lamisil) during oral treatment of cats, experimentally infected with Microsporum canis. , 2002, Journal of veterinary medicine. B, Infectious diseases and veterinary public health.

[7]  M. Drobnič-Košorok,et al.  Determination of terbinafine hydrochloride in cat hair by two chromatographic methods. , 2001, Biomedical chromatography : BMC.

[8]  M. Drobnič-Košorok,et al.  Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats. , 2001, Veterinary microbiology.

[9]  L. Castañón-Olivares,et al.  Effectiveness of terbinafine in the eradication of Microsporum canis from laboratory cats , 2001, Mycoses.

[10]  D. Melamed,et al.  Determination of terbinafine (Lamisil) in human hair by microbore liquid chromatography/tandem mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.

[11]  T. Kotnik Treatment with terbinafine of experimentally infected cats with M. canis: tolerability and side effects of the drug. , 2000 .

[12]  F. Pedonese,et al.  Efficacy of Oral Terbinafine in Feline Dermatophytosis Due to Microsporum Canis , 1999, Journal of feline medicine and surgery.

[13]  P. Kass,et al.  Determination of skin concentrations of enrofloxacin in dogs with pyoderma. , 1998, American journal of veterinary research.

[14]  Lynde,et al.  Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature , 1998, The British journal of dermatology.

[15]  J. Kovarik,et al.  Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites , 1995, Antimicrobial agents and chemotherapy.

[16]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.

[17]  D. Faulds,et al.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. , 1992, Drugs.

[18]  E. Breitschwerdt,et al.  Bone marrow hypoplasia in a cat treated with griseofulvin. , 1991, Journal of the American Veterinary Medical Association.

[19]  T. Jones,et al.  Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. , 1991, Acta dermato-venereologica.